Fortilin, a novel p53 inhibiting protein, in cardiovascular system.

• Project/Area Number: 21790738
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Circulatory organs internal medicine
• Research Institution: Yokohama City University
• Principal Investigator: FUJITA Takayuki 横浜市立大学, 医学部, 助教 (40468202)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 分子心臓病態学 / 心疾患 / p53

Research Abstract

Fortilin overexpression preserves cardiac function in mice model of heart failure. Recent studies indicate that p53 promotes the deterioration of cardiac function. Fortilin is a novel p53 inhibiting protein. In this study, we generated Fortilin transgenic mice that overexpress Fortilin in the hearts. The anthracycline chemotherapy agent developed more severe heart failure in control mice than the Fortilin transgenic mice. These data suggest that Fortilin overexpression may induce preferable effects on cardiac function in heart failure.